gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Bradykinin receptor B2

B2 receptor, B2R
binds bradykinin; mediates bradykinin induced chloride ion flux; plays a role in pain response [RGD, Feb 2006] (from NCBI)
Top mentioned proteins: Angiotensin II, V1a, Kallikrein, CAN, HAD
Papers using B2 receptor antibodies
Move over ZFNs
Gong Zhiyuan, In PLoS ONE, 2010
... The designed amino acid sequences of TALENs (designated as B2L, B2R, B3L, and B3R) were converted to DNA sequences that correspond with the codon usage in silkworm and then synthesized using a commercial service (GenScript).
Papers on B2 receptor
BDKRB2 +9/-9 bp polymorphisms influence BDKRB2 expression levels and NO production in knee osteoarthritis.
Zhao et al., Nanjing, China. In Exp Biol Med (maywood), Feb 2016
UNASSIGNED: The bradykinin B2 receptor (BDKRB2) plays a key role in the inflammation process of osteoarthritis.
Nanofiltrated C1-esterase-inhibitor in the prophylactic treatment of bradykinin-mediated angioedema.
Strassen et al., Ulm, Germany. In Transfusion, Feb 2016
Current therapy consists of B2 bradykinin receptor antagonists, C1-esterase-inhibitor (C1-INH) concentrate, or the kallikrein inhibitor ecallantide.
Genetic analysis of hereditary angioedema in a brazilian family by targeted next generation sequencing.
Pesquero et al., In Biol Chem, Feb 2016
Alterations identified in a few asymptomatic individuals but also found in almost all symptomatic patients, such as p.Ile197Met (HMWK), p.Glu298Asp (NOS3) and p.Gly354Glu (B2R), may also be involved in modulating patient-specific symptoms.
New insights into the stereochemical requirements of the bradykinin B2 receptor antagonists binding.
Perez et al., Barcelona, Spain. In J Comput Aided Mol Des, Jan 2016
For this purpose an atomistic model of the BK B2 receptor was built by homology modeling and subsequently refined embedded in a lipid bilayer by means of a 600 ns molecular dynamics trajectory.
Protective function of Pirfenidone and Everolimus on the development of chronic allograft rejection after experimental lung transplantation.
Lehle et al., Regensburg, Germany. In Histol Histopathol, Jan 2016
On POD 20, all groups showed severe acute rejection (ISHLT A3-4/B1R-B2R).
Kinins and peptide receptors.
Gobeil et al., In Biol Chem, Jan 2016
The biologically active effector entity of RAS is angiotensin receptor-1 (AT-1R), and that of KKS is bradykinin B2 receptor (B2R).
Angiotensin Converting Enzyme Inhibitor-related Angioedema: A Case of an Unexpected Death.
Gey et al., Kars, Turkey. In Iran J Allergy Asthma Immunol, Nov 2015
The treatment of choice in angioedema including fresh frozen plasma, C1 inhibitor concentrations and BRK-2 antagonists (bradykinin B2 receptor antagonists) were used.
Recombinant human C1 esterase inhibitor in the management of hereditary angioedema.
Riedl, San Diego, United States. In Clin Drug Investig, Jul 2015
Four products are approved in the USA for the treatment of acute attacks of HAE, including one human plasma-derived C1-INH therapy, a recombinant human C1-INH product (rhC1-INH), a plasma kallikrein inhibitor and a bradykinin B2 receptor antagonist.
A randomized trial of icatibant in ACE-inhibitor-induced angioedema.
Hoffmann et al., Düsseldorf, Germany. In N Engl J Med, Mar 2015
METHODS: In this multicenter, double-blind, double-dummy, randomized phase 2 study, we assigned patients who had ACE-inhibitor-induced angioedema of the upper aerodigestive tract to treatment with 30 mg of subcutaneous icatibant, a selective bradykinin B2 receptor antagonist, or to the current off-label standard therapy consisting of intravenous prednisolone (500 mg) plus clemastine (2 mg).
An update on the diagnosis and management of hereditary angioedema with abnormal C1 inhibitor.
Davis-Lorton, In J Drugs Dermatol, Feb 2015
On-demand therapy is required for all patients who are diagnosed with HAE and effective options include plasma-derived and recombinant C1 inhibitors, kallikrein inhibitors, and bradykinin B2-receptor antagonists.
[Role of Bradikynin in the Mechanism of Ischemic Preconditioning of the Heart. Prospects of Bradykinin Application in Cardiosurgical Praxis].
Pei et al., In Vestn Ross Akad Med Nauk, 2014
The B2-receptor blocking abolishes antiarrhythmic, infarct reducing effects ofpreconditioning, eliminates IP-induced cardiac tolerance to oxidative stress.
Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche.
Ong et al., Cambridge, United Kingdom. In Nature, 2014
Pathway analyses implicated nuclear hormone receptors, particularly retinoic acid and γ-aminobutyric acid-B2 receptor signalling, among novel mechanisms that regulate pubertal timing in humans.
Downregulation of Bradykinin type 2 receptor expression in cardiac endothelial cells during senescence.
Lindstedt et al., Helsinki, Finland. In J Vasc Res, 2011
Aging cardiac endothelial cells gradually lose their capacity to express BK-2Rs.
Molecular effects of interleukin-1β on dorsal root ganglion neurons: prevention of ligand-induced internalization of the bradykinin 2 receptor and downregulation of G protein-coupled receptor kinase 2.
Schaible et al., Jena, Germany. In Mol Cell Neurosci, 2011
Data show that IL-1beta attenuates internalization of bradykinin B2 receptors, and induces downregulation of GRK2, in DRG neurons.
Change in central kinin B2 receptor density after exercise training in rats.
Buck et al., São Paulo, Brazil. In Auton Neurosci, 2011
In the medulla, chronic exercise could hyperstimulate the kallikrein-kinin system enhancing its efficiency via the increase of bradykinin B2 receptor density, involving this receptor in central cardiovascular control during exercise or stress.
Cardioprotective effects of tanshinone IIA pretreatment via kinin B2 receptor-Akt-GSK-3β dependent pathway in experimental diabetic cardiomyopathy.
Cao et al., Xi'an, China. In Cardiovasc Diabetol, 2010
Tanshinone IIA is cardioprotective in the context of diabetic cardiomyopathy through kinin B2 receptor-Akt-GSK-3beta dependent pathway.
Attenuation of persistent experimental pancreatitis pain by a bradykinin b2 receptor antagonist.
Porreca et al., Tucson, United States. In Pancreas, 2010
Data suggest that spinal dynorphin may maintain pancreatitis pain through direct or indirect activation of BK B2 receptors in the spinal cord.
Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.
Fan et al., Milano, Italy. In N Engl J Med, 2010
Icatibant is a selective bradykinin B2 receptor antagonist.
International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences.
Zuraw et al., Lund, Sweden. In Pharmacol Rev, 2005
The B2 receptor mediates the action of bradykinin (BK) and lysyl-bradykinin (Lys-BK), the first set of bioactive kinins formed in response to injury from kininogen precursors through the actions of plasma and tissue kallikreins, whereas the B(1) receptor mediates the action of des-Arg9-BK and Lys-des-Arg9-BK, the second set of bioactive kinins formed through the actions of carboxypeptidases on BK and Lys-BK, respectively.
Ottawa, Canada. In Unknown Journal, 0001
Icatibant, a selective bradykinin B2 receptor antagonist, has been approved in many countries worldwide for the symptomatic treatment of acute attacks of types I and II hereditary angioedema (HAE) in adults since 2008.
share on facebooktweetadd +1mail to friends